Francesca Gay, MD, PhD
Dr. Francesca Gay is Associate Professor in the University of Torino, Department of Molecular Biotechnology and Health Sciences, and works as hematologist at the SSD Clinical trials in onco-ematology and multiple myeloma, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Italy. She completed her medical degree in 2004 and her fellowship in hematology in 2008 at the University of Torino, Italy. She obtained her PhD in Medicine and Experimental Therapy in 2014.
She is a member of IMS, EMN, SIE, EHA, ESMO and ASH. She is a member of the Educational Committee of IMS, of the ESMO Clinical Practice Guidelines committee, of the EMN Young Board, of the EHA Steering Committee Program and has previously been a member of the EHA Steering Committee Program Advisory Board, of the GIMEMA working Party on Immunotherapy. She is involved in the design, development and coordination of phase I/II/III clinical trials for the treatment of multiple myeloma in tight collaboration with the European Myeloma Network (EMN and EMN Research Italy), and principal investigator in multi-center trials. She worked on several international multi-center projects and data analyses.
Dr. Gay’s main research focuses on the diagnosis and the clinical and experimental treatment of patients with multiple myeloma and associated disorders, particularly of newly diagnosed patients eligible for autologous stem-cell transplantation. Her interests also include the use of new biological molecules, monoclonal antibodies, immunotherapeutic agents, CAR T Cells and stem-cell transplantation techniques.
She is author and co-author of more than 100 papers published in peer reviewed journals, as well as reviewer for several journals including Lancet, Leukemia, Lancet Oncology, Lancet Hematology, Blood Cancer Journal and Haematologica. In 2019 she has been awarded the Bart Barlogie Young Investigator Award by the International Myeloma Society.